CEL-SCI Corporation (AMEX:CVM) jumped 17.17% to close at $0.63 with 1,919,446 shares moving on no official news; however Tuesday at this year’s annual BIO CEO & Investor Conference,  the company’s CEO presented the benefits of its lead cancer therapeutic, Multikine, which was later brutally rebuffed in an online article published by an investment researcher for TheStreet.com, which sent the stock tumbling about 10% that day. Based in Vienna, Virginia, CEL-SCI Corporation researches and develops drugs and vaccines used in the treatment of cancer and viral infections, the company has been actively researching possible variations and eventual mutations of the swine flu.

NexMed, Inc. (NASDAQ:NEXM) up 8.70% to close at $0.039 on no news since the company announced a private placement of $2.3 million; and the sale of its New Jersey state tax credits and net operating losses which raised $438,000 in net proceeds. In January the company announced that pre-clinical results confirmed the ability of the company’s NexACT technology to orally administer chemotherapy drug Taxol, and sent the stock surging 85%. Headquartered in East Windsor, New Jersey, NexMed, Inc. develops bio-enhancement drug delivery technology known as NexACT, which enables an active drug to be better absorbed through the skin.  NexMed has 3 drug candidates at mid stage trial and expects a decision from Health Canada in February 2010 concerning approval of Vitaros, a topical treatment for erectile dysfunction.  NEXM’s 52 week high sits at $0.74; the stock is trading above its 200 day moving average of $0.27, and overall has appreciated 71% in 2010.

Opexa Therapeutics Inc. (NASDAQ:OPXA) advanced 8.81% to close at $2.10, on no news. Based in The Woodlands, Texas, Opexa Therapeutics, Inc. develops patient-specific cellular therapies for the treatment of autoimmune diseases including multiple sclerosis (MS) and diabetes. The proprietary therapies are based on adult stem cell technologies and include a T-cell therapeutic vaccine, Tovaxin, which is in clinical development for the treatment of MS.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

PositiveID Corporation (NASDAQ:PSID) gained 28.20% up to $1.50 with volume surging on no news. PSID is trading above its 200 day moving average of $1.03, and edging closer to its all time high of $1.65. PositiveID Corporation previously conducted business as VeriChip Corporation but changed its name to PositiveID Corporation on November 11^th 2009.   The medical application of the company’s proprietary RFID chip was recently profiled by Forbes, and The Journal of American Chemical Society, touting the technology’s potential to revolutionize the diabetes testing market, worldwide. The diabetes testing market is currently estimated to be valued at about $8 billion; the ever-increasing occurrence of diabetes is resulting in higher volumes of diagnostic tests, which is driving strong growth at an annual rate of about 7 percent.

Headquartered in Delray Beach, Florida, PositiveID Corporation develops, markets, and sells RFID systems to identify, locate, and protect people and assets in the healthcare market  around the world.  The company has business activities in three markets: Healthcare Security, which  is an infant protection system; Implantable serves the VeriMed system, in which human RFID microchips are implanted for patient identification and security purposes; the Industrial application sells vibration monitoring tools for engineering, construction, and mining professionals to measure the effects of human induced vibrations from explosives; and Asset Management systems used by industrial companies to manage and track their mobile equipment and tools.  The ultimate applications of RFID chips are much broader than healthcare and can eventually be used in all forms of identification including banking. In March 2009, PositiveID established a subsidiary, VeriGreen Energy Corporation, to focus and supply the clean and alternative energy sector.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Bioniche Life Sciences (TSE:BNC) surged 50.00% up to $1.05 on news the Canadian based biopharmaceutical company has met two major milestones under its licensing agreement with Endo Pharmaceuticals: Bioniche will receive royalties totalling US$8 million for rights to their drug therapeutic treatment of non-muscle-invasive bladder cancer, Urocidin, in North America.  Furthermore, Endo Pharmaceuticals will execute its exclusive licence to develop and market the drug worldwide, and Endo will all assume the development expenses for the product. 

In July 2009, Bioniche entered into a venture deal with Endo Pharmaceuticals valued at $20 million, to develop and market the cancer drug.  The terms of the agreement projected additional payments of up to $110 million.

Headquartered in Belleville, Ontario, Bioniche Life Sciences Inc is a technology and research-based biopharmaceutical company conducting research, development and commercialization of biopharmaceuticals for human and animal health, along with projects in food safety. 

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) gained 25.26% up to $1.19 on no news; but has been garnering attention from investment researchers this week. RNN stock has gained more than 70% since Monday on heavy volume.  Based in Rockville, Maryland, Rexahn Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company which discovers, develops, and commercializes treatments for cancer, central nervous system disorders, sexual dysfunction in the US. The company currently has three drug candidates in Phase II clinical trials which include Serdaxin for the treatment of depression, Archexin for the treatment of renal cell carcinoma and pancreatic cancer; and Zoraxel for the treatment of sexual dysfunction.

GeoPharma, Inc. (NASDAQ:GORX) gained 11.11% up to $0.301 on no news; however the company is expected to release Q4 results today after the close of the market. . Headquartered in Largo, Florida, GeoPharma researches, develops, manufactures, and brings to market branded generic pharmaceuticals, veterinary products, health products, and functional foods.  The company is registered with both the Food and Drug Administration and the Drug Enforcement Administration.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) gained 13.18% to close at $0.91 on no news with 2,251,436 shares traded. Recently the company granted Carmot Therapeutics, Inc., an exclusive license to its proprietary Fragment-Based Lead Discovery (FBLD) technology. Carmot will use the FBLD technology, called “Chemotype Evolution,” for identifying promising drug candidates in a broad range of therapeutic areas, including inflammatory, metabolic, and neurodegenerative diseases. Sunesis retains full rights to the technology for use in its future internal discovery efforts; however terms of the agreement were not revealed.  The company disclosed promising developments at the end of 2009: a Phase 2 Voreloxin study for leukemia proved that patients who dosed Voreloxin combined with chemotherapy had an increased survival rate. Patients with acute myeloid leukemia usually live for only about three to six months. Headquartered in South San Francisco, California, Sunesis Pharmaceuticals, Inc is a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumour cancers. Its primary product candidate is Voreloxin; an anticancer treatment is in Phase 2 development stage.

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) up 18.27% to close at $2.33 after hitting an intra-day high of $2.43, on no news. The company’s lead drug candidate Seliciclib was examined by two medical journals in January and found to be successful in killing lung cancer cells through induction of cancer cell suicide; the stock jumped 152% to a 52 week high of $2.96. Headquartered in Berkeley Heights, New Jersey, Cyclacel Pharmaceuticals, Inc., is a development-stage biopharmaceutical company which discovers, develops, and commercializes novel, mechanism-targeted drugs to treat human cancers and other serious illnesses.  The company currently has 3 drug candidates in 7 clinical trial studies for the treatment of various cancers.  CYCC is trading above its 200 day moving average of $1.21 and has gained 717% from a low of $0.028 last February.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Harvest Natural Resources, Inc. (NYSE:HNR) jumped 17.08% to close at $5.14 on news the energy company entered into definitive agreements with institutional investors to raise gross proceeds of up to $32 million, through a registered direct offering of 8.25% senior convertible notes due 2013.  The closing of the offering is expected to take place on February 17, 2010. Harvest intends to use the estimated net income of $30 million from the offering to fund capital expenditures, working capital needs and for general corporate purposes. Headquartered in Houston, Texas, Harvest Natural Resources, Inc., is an independent oil and natural gas producer.  Through its subsidiary, Harvest Vinccler, S.C.A., the company has interests in the Bolivarian Republic of Venezuela; and through its 40 percent interests in Petrodelta, S. A., operates a portfolio of properties in eastern Venezuela, including proven oil fields, as well as properties with opportunities for development and exploration.

NGAS Resources, Inc. (NASDAQ:NGAS) gained 15.22% to close at $1.59 on no news.  Based in Lexington, Kentucky, NGAS Resources, Inc., together with its subsidiaries, engages in the exploration and production of natural gas principally in the southern portion of the Appalachian Basin in the eastern US. The company also has interests in a non-operated coal bed methane project in the Arkoma Basin and non-operated projects in West Virginia and Virginia.  NGAS Resources, Inc. own rights to gold and silver properties covering 381 acres in Alaska; and owns and operates distribution systems for retail sales of natural gas in south-central Kentucky.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Geeknet, Inc. (NASDAQ:LNUX) rose 22.46% up to a 52 week high of $1.58 on news the company reported growth during its fourth quarter, and an increase in revenue for the year ending Dec. 31^st 2009 which help to offset net losses from a $1.2 million write-off of software and a $4.6 million impairment charge for an investment in CollabNet.  Highlights of the report note that revenue for the fourth quarter of 2009 grew to $32.6 million from $24.8 million for 2008 Q4.  Net income for the fourth quarter of 2009 slipped to $0.03 per share from $0.04 per share, for the same period in 2008.  Revenue for the twelve months ended December 31, 2009 was $65.6 million compared to $59.4 million for 2008; however net loss for the twelve months ended December 31, 2009 was $14.0 million or $0.23 per share compared to a net loss of $4.8 million or $0.07 per share for the comparable period a year ago. The company also announced it appointed Robert A. Bowman to its Board of Directors on February 8^th.   Headquartered in Mountain View, California, Geeknet is the online network for the global technology community. The company’s network of websites include: SourceForge, Slashdot, ThinkGeek, Ohloh and freshmeat which host about 40 million viewers each month.

Hydrogenics Corporation (USA) (NASDAQ:HYGS) gained 16.19% up to $0.244 on no news. Earlier this week, the company announced an upcoming share consolidation of its issued and outstanding common shares to comply with the NASDAQ’s Minimum Bid Price Rule.  The consolidation will be effective as of March 12th, 2010, and will be executed with a ratio of one post-consolidation share for every 25 pre-consolidation shares. Based in Mississauga, Canada, Hydrogenics Corporation develops and manufactures hydrogen generators and fuel cell products for industrial and clean energy markets in North America and Europe.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Augusta Resource Corp. (USA) (AMEX:AZC) jumped 18.06% up to $2.55 on news the company has signed a mining deal with Silver Wheaton for a cash payment of US$230 million and additional payments of US$3.90 per ounce of silver and US$450 per ounce of gold delivered during the mine life. Headquartered in Vancouver, Canada, Augusta Resource Corp is a mineral resource mining and exploration company.  It holds a 100% interest in the Rosemont property, a copper-molybdenum-silver deposit in Pima County, Arizona that covers unpatented and patented mining claims of approximately 15,000 acres.

Mercer International Inc. (NASDAQ:MERC) gained 12.36% up to $3.91 on news the company reported results for the fourth quarter and year ended December 31, 2009 late yesterday. Operating EBITDA in the fourth quarter of 2009 increased by over 80% to $34.7 million from $18.6 million in the third quarter of 2009. In the fourth quarter of 2008, Mercer had an operating EBITDA loss of $9.9 million. The company noted progress in the last quarter of 2009 was due chiefly to pricing improvements and strong demand from Chinese markets. Headquartered in Vancouver, British Columbia, Mercer International is one of the largest northern bleached softwood kraft pulp producers in the world by production capacity.  The company’s markets are primarily in Europe, Asia and North America, through three subsidiaries consisting of large-scale, modern pulp mills: one in British Columbia and two in eastern Germany.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Mercer International Inc. (NASDAQ:MERC) rose 8.75% to close at $3.48 on no news; however the company is set to release fourth quarter and full year financial results for the period ended December 31,  after the close of the market today. Timber and pulp markets were hit hard by the economic the slowdown last year and showing signs of bouncing back on increased demands by global markets. Headquartered in Vancouver, British Columbia, Mercer International is one of the largest northern bleached softwood kraft pulp producers in the world by production capacity.  The company’s markets are primarily in Europe, Asia and North America, through three subsidiaries consisting of large-scale, modern pulp mills: one in British Columbia and two in eastern Germany.   Mercer’s stock has appreciated 241% since August.

Redhawk Resources, Inc. (CVE:RDK) gained 12.70% to close at $0.355 on no news.  Headquartered in Vancouver, British Columbia,  Redhawk Resources is resource exploration and development company with primary focus on the accelerated development of its advanced stage Copper Creek copper-molybdenum project in San Manuel, Arizona. The company also has two gold/silver properties of merit in Nevada. RDK has gained 294% from a 52 week trading low of $0.09 in March.  There is some technical resistance for RDK at the $0.38 level; however the stock is bullish and currently trading well above its 200 day moving average of $0.200. 

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose 16.00% up to $7.25, on no news since the company reported stellar 2009 Q4 and end of year financial results last week.  Highlights of the report include an increase in net income for the last quarter of 2009 up to $15.2 million, or $0.37 per basic share, compared to net income of $10.1 million, or $0.26 per share for the same quarter of 2008. Total revenues also grew to $74.6 million for the year ended December 31, 2009, up from $56.6 million for the year ended December 31, 2008.  Based in Birmingham, Alabama, BioCryst Pharmaceuticals develops small-molecule drugs for treatment of immunological, viral, and cardiovascular diseases and disorders.  The company’s lead flu drug Peravimir has already begun selling Japan under the name Rapiacta. The US government has approved BioCryst’s Peramivir for the emergency treatment for swine flu. The company expects to continue testing Peramivir until 2011 to win full FDA approval in the U.S. BCRX has gained 494% from a 52 week trading low $1.16 in March.

A.P. Pharma, Inc. (NASDAQ:APPA) gained 15.12% up to $1.90 on no news. In January the company received a milestone royalty payment of $2.5 million for rights to Retin-A Micro and Carac it sold to an affiliate of Paul Capital Healthcare. Based in Redwood City, California, A.P. Pharma, Inc., is a pharmaceutical company developing pharmaceutical products applying its proprietary Biochronomer polymer-based drug delivery technology. Its lead product candidate is APF530, which completed pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting. The New Drug Application (NDA) for APF530 was submitted to the FDA in May 2009 and accepted for review in July 2009, at which time the FDA set a Prescription Drug User Fee Act (PDUFA) date of March 18, 2010.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter